Novartis announces 20% average reduction in price of malaria drug Coartem®
- Details
- Category: Novartis
Novartis has announced a 20% average reduction in the price of Coartem® tablets (artemether/lumefantrine 20 mg/120 mg), the state-of-the-art artemisinin-based combination treatment (ACT) for malaria. Starting this Friday, which is World Malaria Day, this price reduction will increase access to Coartem for millions of malaria patients, especially children in low income regions of Africa.
The Medicines Company Reports First Quarter 2008 Financial Results
- Details
- Category: Financial
The Medicines Company (NASDAQ: MDCO) today announced its financial results for the first quarter of 2008. Financial highlights for the first quarter of 2008:
- Net revenue increased by 19% to $79.4 million for the first quarter of 2008 from $66.6 million for the first quarter of 2007.
Environmentally Responsible Site to Significantly Increase Company's Presence in China
- Details
- Category: Genzyme
Genzyme Corp. (Nasdaq: GENZ) announced today that it will build a major new research and development center in Beijing. The initiative is an important element in Genzyme's ongoing global expansion and commitment to establishing a long-term presence in China.
Results from phase 2b "DEEP" study in severe pre-eclampsia
- Details
- Category: Clinical Trials
Protherics PLC, the international biopharmaceutical company focused on critical care and cancer, today announces that its placebo-controlled phase 2b Digoxin Immune Fab (DIF) Efficacy Evaluation in Pre-eclampsia ("DEEP") study in severe pre-eclampsia has met one of its two primary endpoints.
Bayer Challenges Watson and Sandoz U.S. ANDA Filings on Yasmin®
- Details
- Category: Bayer
Bayer confirmed that Bayer Schering Pharma AG and Bayer HealthCare Pharmaceuticals Inc. filed a patent infringement lawsuit in U.S. Federal Court in the Southern District of New York (New York) against Watson Pharmaceuticals, Inc., Watson Laboratories, Inc. and Sandoz, Inc.
FTY720, a novel oral therapy in development for multiple sclerosis
- Details
- Category: Novartis
The investigational oral therapy FTY720 (fingolimod) continues to demonstrate sustained benefits in patients with multiple sclerosis (MS) after three years of treatment, according to new clinical data presented from an ongoing Phase II study extension[1].
GlaxoSmithKline and Regulus Therapeutics form strategic alliance
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) and Regulus Therapeutics LLC (Regulus) announced a worldwide strategic alliance to discover, develop and market novel microRNA-targeted therapeutics to treat inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.
More Pharma News ...
- Bayer donates €250,000 for patients with hemophilia
- Grindeks JSC is opening new representative office in Uzbekistan
- Pfizer Reports First-Quarter 2008 Results
- Abbott Reports Double-Digit Sales and Earnings Growth in First Quarter
- Roche fully acquires privately-owned biotech company Piramed
- Patients with early Parkinson's disease show better symptom control
- AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy